Hepatitis B Vaccine Available in Great Britain

Dynavax Technologies Corporation today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency had granted Marketing Authorization in Great Britain for HEPLISAV B® for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults.

"Hepatitis B is a highly infectious and potentially deadly virus with increasing infection rates, and over 250 million people infected worldwide. Thankfully, it can be prevented with effective vaccination," commented Ryan Spencer, Chief Executive Officer of Dynavax, in a press release on February 28, 2023.

HEPLISAV-B combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor 9 agonist adjuvant CpG 1018 to enhance the immune response.

HEPLISAV-B is indicated for preventing infection caused by all known subtypes of HBV in adults aged 18 years and older in the U.S.